Sonelokimab

• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending
  2025-522471-28-00 Phase III 16 countries MoonLake Immunotherapeutics AG
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting
  2025-520564-17-00 Phase III 13 countries MoonLake Immunotherapeutics AG
• A Phase 2, open-label, imaging study to explore the effects of sonelokimab in patients with active psoriatic arthritis or axial spondyloarth… Recruiting
  2024-514504-13-00 Phase II 1 country MoonLake Immunotherapeutics AG
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting
  2024-516219-25-00 Phase III 7 countries MoonLake Immunotherapeutics AG
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended
  2024-516213-20-00 Phase III 16 countries MoonLake Immunotherapeutics AG
• A Phase 2 open-label imaging study to explore the effects of sonelokimab in patients with active axial spondyloarthritis Ended
  2024-513498-36-00 Phase II 1 country MoonLake Immunotherapeutics AG
• A Phase 2, multicentre, open-label study of sonelokimab in patients with moderate-to-severe pustulosis palmoplantaris Ended
  2024-513305-32-00 Phase II 1 country MoonLake Immunotherapeutics AG
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511360-87-00 Phase III 8 countries MoonLake Immunotherapeutics AG
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511363-28-00 Phase III 10 countries MoonLake Immunotherapeutics AG

Showing 1–9 of 9 trials